Insulet CORP

Insulet Corporation has appointed former IDEXX Laboratories CEO Jonathan J. Mazelsky as an independent director effective July 1, 2026.

Insulet Corporation is initiating a voluntary medical device correction for specific lots of Omnipod products due to a manufacturing issue that could lead to insulin under-delivery.

Insulet Corporation announced robust first-quarter 2026 financial results, exceeding revenue guidance and raising its full-year outlook, driven by strong Omnipod sales and strategic product launches.

Insulet Corporation initiated a voluntary medical device correction for specific Omnipod 5 Pods due to a manufacturing issue, expecting up to $40 million in related costs.

Insulet Corporation has formalized the severance agreement with former Chief Financial Officer Ana M. Chadwick, aligning with previously disclosed terms.

Insulet Corporation filed an amended 8-K to confirm Grant Thornton's audit completion and its dismissal, with PricewaterhouseCoopers taking over as the independent auditor for fiscal year 2026.

Insulet Corporation reported a 33.9% increase in total revenue for the first quarter of 2026, driven by strong performance of its Omnipod 5 system and international expansion.

Insulet Corporation reported robust third-quarter revenue growth of 29.9% to $706.3 million, driven by strong Omnipod product sales and international expansion.

Insulet Corporation announced robust Q2 2025 revenue growth and improved gross margins, despite a net income decline driven by debt extinguishment costs and prior-year tax benefits.

Insulet Corporation's Q1 2025 revenue increased by 28.8% year-over-year, primarily driven by increased sales volume of the Omnipod platform and drug delivery systems.

Insulet Corporation's Q3 2024 results show significant revenue growth, driven by increased adoption of the Omnipod 5 system and international expansion.

Insulet Corporation's Q2 2024 results show significant revenue growth and a substantial increase in net income, primarily driven by the adoption of the Omnipod 5 system.

Insulet Corporation's 2024 annual report reveals significant revenue growth driven by the adoption of Omnipod 5 and expansion into international markets.

Insulet Corporation's recent filings detail an amendment to a purchase agreement with NXP USA, Inc., and the release of its annual report, showcasing the company's financial performance, strategic initiatives, and future outlook.

Robert Huffines, a Director at Insulet Corporation, has amended a prior filing to correct the number of deferred stock units acquired and the price per unit.

Director Robert Huffines of Insulet Corporation acquired 144 shares of common stock through a deferred compensation plan.

Insulet Corporation Director Timothy C. Stonesifer purchased 2,790 shares of common stock at $143.51 per share.

Insulet Corporation Director Luciana Borio sold 418 shares of common stock at a price of $143.27 per share.

Insulet Corporation reports a Form 4 filing detailing a stock purchase by Director Elizabeth H. Weatherman.

Director Elizabeth H. Weatherman acquired 1,660 shares of common stock in Insulet Corp through an annual equity award.

Insulet Corporation reports strong 2025 financial performance with 30% revenue growth and outlines strategic leadership transitions.

Insulet Corporation will hold its 2025 Annual Meeting of Shareholders virtually on May 22, 2025, and the proxy statement details key proposals, including the election of directors and executive compensation.

Insulet Corporation has filed a definitive proxy statement with the Securities and Exchange Commission.

Insulet's proxy statement highlights a year of exceptional financial success and operational milestones, driven by the strong adoption of the Omnipod 5 system.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 5.6% of Insulet Corp's common stock as of March 31, 2026.

Vanguard Capital Management has reported a beneficial ownership of 7.49% in Insulet Corp's common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership of Insulet Corp common stock following an internal realignment.

FMR LLC and Abigail P. Johnson report a 9.0% beneficial ownership stake in Insulet Corp as of December 31, 2025, in an amended Schedule 13G filing.

The Vanguard Group has reported a 12.49% beneficial ownership stake in Insulet Corp, holding 8,796,200 shares of common stock.

Capital Research Global Investors has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in Insulet Corp. as of June 30, 2025.